Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-1-17
pubmed:abstractText
Amyloid beta (Abeta) immunotherapy for Alzheimer's disease has shown initial success in mouse models of Alzheimer's disease and in human patients. However, because of meningoencephalitis in clinical trials of active vaccination, approaches using therapeutic antibodies may be preferred. As a novel antigen to generate monoclonal antibodies, the current study has used Abeta oligomers (amyloid beta-derived diffusible ligands, ADDLs), pathological assemblies known to accumulate in Alzheimer's disease brain. Clones were selected for the ability to discriminate Alzheimer's disease from control brains in extracts and tissue sections. These antibodies recognized Abeta oligomers and fibrils but not the physiologically prevalent Abeta monomer. Discrimination derived from an epitope found in assemblies of Abeta1-28 and ADDLs but not in other sequences, including Abeta1-40. Immunoneutralization experiments showed that toxicity and attachment of ADDLs to synapses in culture could be prevented. ADDL-induced reactive oxygen species (ROS) generation was also inhibited, establishing this response to be oligomer-dependent. Inhibition occurred whether ADDLs were prepared in vitro or obtained from Alzheimer's disease brain. As conformationally sensitive monoclonal antibodies that selectively immunoneutralize binding and function of pathological Abeta assemblies, these antibodies provide tools by which pathological Abeta assemblies from Alzheimer's disease brain might be isolated and evaluated, as well as offering a valuable prototype for new antibodies useful for Alzheimer's disease therapeutics.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0022-3042
pubmed:author
pubmed:issnType
Print
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-35
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17116235-Alzheimer Disease, pubmed-meshheading:17116235-Amyloid beta-Peptides, pubmed-meshheading:17116235-Animals, pubmed-meshheading:17116235-Antibodies, Monoclonal, pubmed-meshheading:17116235-Antibody Specificity, pubmed-meshheading:17116235-Brain, pubmed-meshheading:17116235-Calmodulin-Binding Proteins, pubmed-meshheading:17116235-Cells, Cultured, pubmed-meshheading:17116235-Dose-Response Relationship, Drug, pubmed-meshheading:17116235-Epitopes, pubmed-meshheading:17116235-Glial Fibrillary Acidic Protein, pubmed-meshheading:17116235-Humans, pubmed-meshheading:17116235-Immunoblotting, pubmed-meshheading:17116235-Immunohistochemistry, pubmed-meshheading:17116235-Mice, pubmed-meshheading:17116235-Neurons, pubmed-meshheading:17116235-Peptide Fragments, pubmed-meshheading:17116235-Protein Binding, pubmed-meshheading:17116235-Rabbits, pubmed-meshheading:17116235-Reactive Oxygen Species, pubmed-meshheading:17116235-Tetrazolium Salts, pubmed-meshheading:17116235-Thiazoles
pubmed:year
2007
pubmed:articleTitle
Monoclonal antibodies that target pathological assemblies of Abeta.
pubmed:affiliation
Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural